172 related articles for article (PubMed ID: 33221963)
21. BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells.
Kwon T; Chandimali N; Huynh DL; Zhang JJ; Kim N; Bak Y; Yoon DY; Yu DY; Lee JC; Gera M; Ghosh M; Park YH; Jeong DK
Cell Death Dis; 2018 Feb; 9(2):244. PubMed ID: 29445170
[TBL] [Abstract][Full Text] [Related]
22. TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.
Xu W; Wei Y; Li Y; Yin Y; Yuan W; Yang Y; Zhao W; Wu J
Oncol Rep; 2017 Sep; 38(3):1815-1821. PubMed ID: 28737828
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
24. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
25. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
26. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
27. A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells.
Li XQ; Yue CW; Xu WH; Lü YH; Huang YJ; Tian P; Liu T
Biomed Pharmacother; 2020 Aug; 128():110322. PubMed ID: 32505822
[TBL] [Abstract][Full Text] [Related]
28. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
29. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
30. Different mechanisms of cisplatin resistance development in human lung cancer cells.
Okamoto K; Saito Y; Narumi K; Furugen A; Iseki K; Kobayashi M
Biochem Biophys Res Commun; 2020 Oct; 530(4):745-750. PubMed ID: 32782152
[TBL] [Abstract][Full Text] [Related]
31. Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway.
Sun Y; Chen Y; Xu M; Liu C; Shang H; Wang C
Biomed Res Int; 2020; 2020():9243681. PubMed ID: 32685545
[TBL] [Abstract][Full Text] [Related]
32. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
[TBL] [Abstract][Full Text] [Related]
33. The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis.
Li G; Li M; Hu J; Lei R; Xiong H; Ji H; Yin H; Wei Q; Hu G
Oncogene; 2017 Feb; 36(7):989-998. PubMed ID: 27641336
[TBL] [Abstract][Full Text] [Related]
34. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
35. [Increased expression of acetaldehyde dehydrogenase in cisplatin-resistant human lung adenocarcinoma A549/DDP cells].
He J; Song X; Yu L; Li J; Qiao Z; Jiu R; Yu B; Liu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 May; 31(5):625-9. PubMed ID: 25940289
[TBL] [Abstract][Full Text] [Related]
36. Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma.
Wang Q; Cheng N; Li X; Pan H; Li C; Ren S; Su C; Cai W; Zhao C; Zhang L; Zhou C
Oncotarget; 2017 Jan; 8(2):2558-2567. PubMed ID: 27911863
[TBL] [Abstract][Full Text] [Related]
37. Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma.
Yun X; Zhang K; Wang J; Pangeni RP; Yang L; Bonner M; Wu J; Wang J; Nardi IK; Gao M; Raz DJ
Mol Cancer Res; 2018 Jul; 16(7):1161-1171. PubMed ID: 29720480
[TBL] [Abstract][Full Text] [Related]
38. Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3β-AP1/Snail and JNK-AP1 pathways.
Pan CH; Chen SY; Wang JY; Tsao SP; Huang HY; Wei-Chen Chiu P; Wu CH
Chem Biol Interact; 2020 Dec; 332():109304. PubMed ID: 33164868
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-383 is a tumor suppressor in human lung cancer by targeting endothelial PAS domain-containing protein 1.
Ma H; Liu B; Wang S; Liu J
Cell Biochem Funct; 2016 Dec; 34(8):613-619. PubMed ID: 27862077
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer.
Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
